Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 7 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $1.33B
- Insider buysLast 90 days, $6.35M in total
- 7
- Insider sellsLast 90 days, $279.0K in total
- 2
- 13F holdersQ2 2026, +30 vs. previous quarter
- 162
- 13F valueReported value at the end of Q2 2026
- $1.36B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.30M
- +550.0% year over year
- Net income, FY2025
- -$140.1M
- −108.3% year over year
- Free cash flow, FY2025
- -$129.8M
- No comparable prior period
- Revenue, Q2 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $140.1M (10773.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.39M
- Shares sold short
- Change
- −27.9K
- −0.8% vs. previous
- Days to cover
- 10.00
- At average daily volume
Superinvestors holding INBX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Inhibrx Biosciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.3%
Inhibrx Biosciences, Inc.'s share of the portfolio
- Shares
- 1,123,929
- Value
- $106.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Inhibrx Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 (view filing)6:58 PM ET | Oct 14 | Same day | Lappe MarkChief Executive Officer | PPurchase | +10.0K | $84.56 | +$849.0K | +6.3%170.0K after | 6 lots |
| Sep 28, 2026 (view filing)5:47 PM ET | Sep 25-28 | 3 days | Lappe MarkChief Executive Officer | PPurchase | +10.0K | $99.88 | +$998.8K | +1.4%740.5K after | 4 lots |
| Sep 23, 2026 (view filing)4:59 PM ET | Sep 23 | Same day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $100.00 | +$500.0K | +1.2%434.4K after | |
| Sep 17, 2026 (view filing)5:46 PM ET | Sep 16 | 1 day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $100.00 | +$500.0K | +1.2%429.4K after | |
| Sep 15, 2026 (view filing)5:52 PM ET | Sep 11-15 | 4 days | Manhard KimberlyDirector | SSale | −1.50K | $109.03 | −$163.5K | −16.7%7.50K after | 3 lots |
| Sep 10, 2026 (view filing)7:06 PM ET | Sep 8-9 | 2 days | Manhard KimberlyDirector | SSale | −1.00K | $115.47 | −$115.5K | −10.0%9.00K after | 2 lots |
| Sep 8, 2026 (view filing)5:23 PM ET | Sep 8 | Same day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $113.52 | +$567.6K | +1.2%424.4K after | |
| Sep 8, 2026 (view filing)4:26 PM ET | Sep 8 | Same day | Forsyth DouglasDirector | PPurchase | +2.50K | $114.65 | +$286.6K | +1.1%227.1K after | |
| Sep 8, 2026 (view filing)4:04 PM ET | Sep 8 | Same day | Lappe MarkChief Executive Officer | PPurchase | +25.0K | $105.82 | +$2.65M | +3.5%730.5K after | 6 lots |
| Oct 9, 2025 (view filing)4:41 PM ET | Oct 7 | 2 days | Viking Global Investors LP and 7 others10% Owner | SSale | −350.0K | $32.25 | −$11.3M | −77.3%102.9K after | 3 lots |
Top 10 13F holders, Q2 2026
See all 162 holdersThe largest institutional positions in Inhibrx Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 1,308,051 | $123.9M | 0.01% | +44,973+3.6% | Added |
| Perceptive Advisors LLC | 1,297,763 | $123.0M | 1.91% | −144,944−10.0% | Reduced |
| Sanofi | 1,157,926 | $109.7M | 20.54% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 1,123,929 | $106.5M | 0.30% | −313,776−21.8% | Reduced |
| HighTower Advisors, LLC | 870,551 | $82.5M | 0.08% | +3510.0% | Added |
| Bank of America Corp | 841,141 | $79.7M | 0.01% | +808,458+2,473.6% | Added |
| BlackRock, Inc. | 825,972 | $78.3M | 0.00% | +27,074+3.4% | Added |
| Schonfeld Strategic Advisors LLC | 697,586 | $66.1M | 0.35% | +442,759+173.7% | Added |
| State Street Corp | 640,458 | $60.7M | 0.00% | +89,613+16.3% | Added |
| Vanguard Capital Management LLC | 492,477 | $46.7M | 0.00% | +6,055+1.2% | Added |
Holders of 5% or more of INBX
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Inhibrx Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 13G/A | 9.99%1.49M shares | 0.00 ppfrom 9.99% | Nov 14, 20243 filings | Aug 14, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G/A | 9.30%1.38M shares | −0.69 ppfrom 9.99% | Jun 7, 20244 filings | Aug 14, 2026 | SEC |
| Morgan Stanley | 13G | 7.90%1.16M shares | New | Feb 11, 20261 filing | Feb 11, 2026 | SEC |
| Kayyem Jon Faiz | 13D/A | 7.90%1.15M shares | – | Jun 3, 20242 filings | Feb 26, 2025 | SEC |
| Lappe Mark | 13D/A | 6.40%925.4K shares | – | Jun 3, 20242 filings | Feb 26, 2025 | SEC |